Michael Rossi joined Mirion Technologies in October 2022 and held the Medical Group President position until November 2023. While at Mirion, he received restricted stock units (RSUs) that began vesting on November 1, 2022. By the end of 2022, he...

Michael Rossi joined Mirion Technologies in October 2022 and held the Medical Group President position until November 2023. While at Mirion, he received restricted stock units (RSUs) that began vesting on November 1, 2022. By the end of 2022, he held 80,445 RSUs valued at over $531,000 based on the stock price at that time. Since joining Y-mAbs, the transition from Mirion marks a significant shift in his career, as he takes on new responsibilities as CEO. His previous holdings in Mirion illustrate a solid investment backing based on his growing wealth in the field, which likely reflects positive trends in the radiopharmaceutical market.